The third-generation tyrosine kinase inhibitor (TKI) ponatinib shows activity against all
common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant …

BCR-ABL1 kinase domain mutations can confer resistance to first-and second-generation
tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). In preclinical studies …

Background Secondary mutations in BCR-ABL are the most common cause of resistance to
TKIs in patients (pts) with chronic myeloid leukemia (CML). Ponatinib is a potent pan-BCR …

Background Ponatinib is a potent, oral, pan-BCR-ABL inhibitor with activity against native
and mutant forms of BCR-ABL, including the tyrosine kinase inhibitor (TKI)-resistant T315I …

The third-generation tyrosine kinase inhibitor (TKI) ponatinib exerts a strong anti-neoplastic
effect in all stages of chronic myeloid leukemia (CML) as well as in Philadelphia (Ph) …

Background Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated
BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor–refractory threonine-to …

The advent of tyrosine kinase inhibitor (TKI) therapy has considerably improved the survival
of patients suffering chronic myelogenous leukemia (CML). Indeed, inhibition of BCR-ABL …

Abstract Abstract 915 Background: Many patients (pts) with advanced Ph+ leukemias
experience failure of all currently available tyrosine kinase inhibitors (TKIs) targeting BCR …

Development of BCR-ABL tyrosine kinase inhibitors (TKIs) have improved outcomes for
patients diagnosed with chronic myeloid leukemia and Philadelphia chromosome positive …

Abstract Abstract 163 Background: Despite progress in Ph+ leukemia therapy, patients who
experience failure of tyrosine kinase inhibitors (TKIs) and those with the T315I BCR-ABL …